Dear Editor, Hyperactivation of mechanistic target of rapamycin (mTOR) signaling is frequently observed in cancer and aging. 1-3 However, the cellular protective function of mTOR inactivation remains poorly characterized, which may explain the limited therapeutic efficacy of mTOR inhibitors in liver cancer. 4 Accumulating evidence suggests systematic coordination between growth factorreceptor axis and mTOR signaling. 5-8 Here, we focused on MET, a tyrosine kinase receptor for hepatocyte growth factor (HGF) 9,10 and a novel regulator of the mTOR machinery. 7,11 We observed amino acids (AA)-enhanced phosphorylation of the ribosomal protein S6 kinase 1 (S6K1), a biomarker of mTOR activation, was repressed in MET knockout (KO) HepG2 cells. This phenomenon could be rescued by forced expression of wild-type (WT) MET (Figure S1A). In support of this, the MET inhibitor Capmatinib exhibited near-total inhibition of S6K1 phosphorylation (Figure S1B). Furthermore, we found reintroduction of a kinase-dead (KD) MET mutant was unable to rescue MET KO-caused mTOR inactivation (Figure S1C), while a constitutively active translocated promoter region fused to MET (TPR-MET) mutant enhanced AAstimulated S6K1 phosphorylation (Figure S1D), suggesting MET mediates AA-mTOR signaling pathway in a phosphorylation-dependent manner. Interestingly, AA-stimulated mitochondrial oxidative phosphorylation (OXPHOS), including oxidationreduction reaction (Figures S2A and B) and ATP production (Figures S2C and D), was severely compromised